Indantadol HCl NEW
| Price | $195 | $430 | $636 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-26 |
Product Details
| Product Name: Indantadol HCl | CAS No.: 202914-18-9 |
| Purity: 98.24% | Supply Ability: 10g |
| Release date: 2025/07/26 |
Product Introduction
Bioactivity
| Name | Indantadol HCl |
| Description | Indantadol HCl (CHF-3381) is a NMDA antagonist and nonselective MAO inhibitor. |
| In vivo | In a human heat-capsaicin-induced pain model, Indantadol HCl at a dose of 500 mg effectively reduced the area of secondary hyperalgesia to 67%. Indantadol HCl undergoes extensive liver metabolism, withthe formation of two major metabolites - CHF-3567 and 2-aminoindane. The drug is excreted in urine partially as the parent compound, but mostly as CHF-3567. The tolerability profile of Indantadol HCl at single doses up to 600 mg and twice-daily doses up to 400 mg in clinical trials was significantly more favorable than for other NMDA antagonists. Most side effects have been observed to be mild, and include dizziness and asthenia. Indantadol HCl is currently in phase II clinical trials in patients with diabetic peripheral neuropathic pain.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (220.56 mM), Sonication is recommended. |
| Keywords | V3381 | V 3381 | NMDA | MAO | Indantadol HCl | Indantadol | GT3381 | GT 3381 | CNP3381 | CNP 3381 | CMP3381 | CMP 3381 | CHF3381 | CHF 3381 |
| Inhibitors Related | Hydroxyamine hydrochloride | Mephenesin | Hydralazine hydrochloride | Safinamide | Halothane | Azure B | Paeonol | Isatin | Riluzole | Furazolidone | O-Phospho-L-serine | Procaine hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $20.00/25Kg/Bag |
VIP6Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2021-10-08 | |
| $0.00/25Kg/Bag |
Sinoway Industrial co., ltd.
|
2022-08-09 | ||
| $0.00/25KG |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-05-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY